可注射组织工程肝改善大鼠肝纤维化的作用及其机制  

Effect of liver tissue engineering on liver fibrosis in rats and its probable molecular mechanism

作　　者：周海洋[1] 郑爱民[1] 高卓[1] 黄蓉蓉[1] 张海宏[1] 曹厚军[1] 

机构地区：[1]解放军空军总医院普通外科,北京100700

出　　处：《临床军医杂志》2014年第1期1-4,共4页Clinical Journal of Medical Officers

基　　金：国家863高技术研究发展计划资助项目(2009AA043801)

摘　　要：目的探讨可注射工程化肝组织抗肝纤维化作用及其机制。方法制作大鼠肝纤维化模型,采用新生大鼠肝细胞、液态鼠尾胶原复合物行肝纤维化大鼠肝包膜下多点注射,20 d后计算大鼠生存率、行腹部超声检查、取肝脏观察大体及镜下变化并检测肝组织TGF-β的表达,观察肝脏原位多点注射工程化肝组织对大鼠肝纤维化的影响。结果实验组大鼠镜下及超声检查提示肝纤维化缓解,TGF-β表达明显下降。结论原位多点注射基于新生大鼠肝细胞构建的工程化肝组织能缓解肝纤维化,机制可能与其显著抑制TGF-β的表达有关。Objective To study the treatment of the injectable tissue engineered liver for hepatic fibrosis and its mechanism. Methods After injection of engineered liver tissue on liver fibrosis rats, the function was observed by survival, abdominal ultrasound, HE staining, and immunohistochemical assay of transforming growth factor-β （TGF-β） expression in the liver. Results The survival rate of rats increased. HE staining and ultrasound examinations showed remission of liver fibrosis. TGF-β expression was signifi- cantly decreased. Conclusion In case of multi-point injection in situ, tissue engineering liver based on neonatal rat hepatocytes helps to relieve liver fibrosis, and the mechanism may be related to significant inhibition of TGF-β expression.

关 键 词：肝纤维化 肝组织工程 新生大鼠肝细胞 转化生长因子-Β 

分 类 号：R575.2[医药卫生—消化系统]